A rational approach to evaluation of therapeutic equivalence of nanosimilars: a challenge for formulary selection

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: FLüHMANN, Beat (., Zürich, Switzerland)
  • Co-author(s): Beat Flühmann:
    Stefan Mühlebach: Regulatory Science, Vifor Pharma Ltd, Zürich, Switzerland
  • Abstract:

    Background

    Today up to 23 nanomedicines are approved, and approximately 50 are in clinical development. First nanosimilars have entered the European market through the generic approval pathway, but significant clinical differences have been observed. Many hospital pharmacists are unaware of the specific characteristics of nanomedicines and the..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login